Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. The program was completed in collaboration with Dalton Pharma Services and established a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities.
This milestone strengthens the company's chemistry, manufacturing, and controls (CMC) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. According to the company, the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumours.
The completion of the analytical reference standard program is a critical step in ensuring the quality and consistency of ONC010, which is essential for regulatory submissions and eventual clinical trials. By establishing a qualified reference standard, Onco-Innovations can more effectively conduct analytical testing and maintain manufacturing consistency, which are key requirements for advancing a drug candidate through development.
The company's focus on solid tumours addresses a significant unmet medical need, as solid tumours account for the majority of cancer cases worldwide. Onco-Innovations' proprietary technology aims to provide new treatment options for patients with limited alternatives.
For more information about Onco-Innovations and its progress, visit the company's newsroom at https://ibn.fm/ONNVF. The full press release is available at https://ibn.fm/EefIN.
